Use of Biologic Therapies With Different Mechanisms of Action (MOA) in the First-line (1L) Treatment of Crohn's Disease (CD) in the US

被引：0
作者：
Huang, Zhongwen [1 ]
Ba, Yi [1 ]
Kamble, Pravin [1 ]
Wang, Song [1 ]
机构：
[1] Takeda, Cambridge, MA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S917
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
[21]   Dose Escalation of Biologic Therapies in Biologic Treatment-Naive Patients With Crohn's Disease: Results From the ODESSA-CD Study [J].
Cleveland, Noa Krugliak ;
Kathe, Niranjan ;
Umashankar, Kandavadivu ;
Mirchandani, Kirti ;
Hait, Arunima ;
Paul, Riyanka ;
Ghosh, Sabyasachi ;
Candela, Ninfa ;
Fan, Tao ;
Rubin, David T. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10) :S570-S571
[22]   REAL-WORLD EFFECTIVENESS OF FIRST-LINE BIOLOGIC VEDOLIZUMAB IN CROHN'S DISEASE: ANALYSIS OF HIGHER TREATMENT EFFECT SUBPOPULATION FROM THE EVOLVE STUDY [J].
Yarur, Andres ;
Bressler, Brian ;
Wang, Song ;
Adsul, Shashi ;
Kamble, Pravin ;
Luo, Michelle ;
Cook, Erin ;
Sajeev, Gautam ;
Dieye, Ibou ;
Mantzaris, Gerassimos J. .
GASTROENTEROLOGY, 2021, 160 (06) :S4-S4
[23]   4 Years of Experience with Vedolizumab (Entyvio®) as a First-line Biologic for Treating Ulcerative Colitis and Crohn's Disease in Clinic and Practice [J].
不详 .
VISCERAL MEDICINE, 2018, 34 (05) :400-400
[24]   First-Line Treatment Options for Ileocecal Crohn's Disease: Early Surgical Resection or Biologics? Reply [J].
Agrawal, Manasi ;
Colombel, Jean-Frederic ;
Allin, Kristine H. .
GASTROENTEROLOGY, 2024, 166 (02) :363-364
[25]   Patterns of care in renal cell carcinoma (RCC): Impact of duration of first-line (1L) treatment on second-line (2L) treatment choice [J].
Feinberg, Bruce A. ;
Garofalo, David ;
Drenning, Jason ;
Montgomery, Jim .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[26]   Vedolizumab: First-line Biologic for Ulcerative colitis and Crohn's Disease Real-world Data shows continued stable Disease Progression [J].
Ruedesheim, Sabine M. .
VISCERAL MEDICINE, 2023, 39 (3-4) :100-100
[27]   Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC) [J].
Sotelo, Miguel ;
Chara, Luis ;
Riquelme, Alejandro ;
Toro, Piedad ;
Lopez, Cynthia ;
Hernando, Susana ;
Caviedes, Edinson ;
Aguayo, Cristina ;
Bueno, Coralia ;
Mielgo Rubio, Xabier .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1340-S1341
[28]   Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US) [J].
Mato, Anthony R. ;
Ravelo, Arliene ;
MyTo, Tu ;
Schuldt, Robert ;
Biondo, Juliana M. L. .
BLOOD, 2021, 138
[29]   Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting. [J].
Geynisman, Daniel M. ;
Kish, Jonathan K. ;
Falkenstein, Angelica ;
Huo, Stephen ;
Del Tejo, Viviana ;
Rosenblatt, Lisa ;
Guttenplan, Sarah ;
Balanean, Alexandrina ;
Feinberg, Bruce A. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30]   Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US). [J].
Tran, Nguyen H. ;
Soefje, Scott A. ;
Rangarajan, Nivedita ;
Purushotham, K. ;
Nadig, Mihika ;
Wagner, Tyler E. ;
Valerio, Stephen J. ;
Anderson, Rye ;
Olson, Jody C. .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) :572-572
12345